News is a concise, evidence-aware briefing on what matters in healthcare—new trials, guideline changes, drug approvals, device safety, and health-policy shifts.
The company will spend approximately $1.5 billion in capital investments to grow its U.S. plasma-based manufacturing capabilities over the next five years.
South Korea’s Boryung Corporation continues to boost its production footprint by kicking off a project that will double the capacity of its penicillin manufacturing facility in its home country.
Since the start of the month, several drug recalls have entered the FDA’s periphery, affecting products ranging from hospital drugs and potassium deficiency injections to antibiotics and a generic medicine for attention-deficit/hyperactivity
This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.
Cencora plans to spend $1 billion over the next five years to expand its operations in the U.S., including opening a second national distribution center in Ohio.
Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite
AstraZeneca is pouring $136 million more into the expansion of an inhalants production base in China, bringing its total investment at the site to $886 million.
Teva issued a voluntary recall of 580,844 bottles of the widely used blood pressure medication prazosin hydrochloride, citing unacceptable levels of potentially cancer-causing impurities.
Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection